Education
About Us
Working with TipRanks
Follow Us
Helius Medical Technologies (HSDT)
NASDAQ:HSDT
HSDT Stock Chart & Stats
$6.87
-$0.04(-5.47%)
At close: 4:00 PM EST
$6.87
-$0.04(-5.47%)
Day’s Range― - ―
52-Week Range$5.37 - $1,200.00
Previous CloseN/A
Volume68.49K
Average Volume (3M)1.55M
Market Cap
$276.86M
Enterprise Value-$4.96M
Total Cash (Recent Filing)$6.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 07, 2025EPS Estimate
-128.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,299,220
10 Day Avg. Volume1,311,391
30 Day Avg. Volume1,547,142
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-16.80
Enterprise Value/Gross Profit18.84
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$9.50Price Target Upside38.28% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical ResultsHSDT announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis.
Partnerships And ApprovalsUnitedHealthcare has approved reimbursement for the PoNS device, adding a second private payer to provide coverage.
Bears Say
Financial PerformanceHSDT reported lower-than-expected 1Q25 revenue, as adoption of the PoNS device remains inconsistent.
Reimbursement ChallengesThe ongoing reimbursement headwind continues to limit access to key patient populations and suppress near-term growth.
Helius Medical Technologies News
HSDT FAQ
What was Helius Medical Technologies’s price range in the past 12 months?
Helius Medical Technologies lowest stock price was $5.37 and its highest was $1200.00 in the past 12 months.
What is Helius Medical Technologies’s market cap?
Helius Medical Technologies’s market cap is $276.86M.
When is Helius Medical Technologies’s upcoming earnings report date?
Helius Medical Technologies’s upcoming earnings report date is Aug 07, 2025 which is 75 days ago.
How were Helius Medical Technologies’s earnings last quarter?
Helius Medical Technologies released its earnings results on May 08, 2025. The company reported -$8.7 earnings per share for the quarter, the consensus estimate of -$8.7 by $0.
Is Helius Medical Technologies overvalued?
According to Wall Street analysts Helius Medical Technologies’s price is currently Undervalued.
Does Helius Medical Technologies pay dividends?
Helius Medical Technologies does not currently pay dividends.
What is Helius Medical Technologies’s EPS estimate?
Helius Medical Technologies’s EPS estimate is -128.5.
How many shares outstanding does Helius Medical Technologies have?
Helius Medical Technologies has 40,299,220 shares outstanding.
What happened to Helius Medical Technologies’s price movement after its last earnings report?
Helius Medical Technologies reported an EPS of -$8.7 in its last earnings report, expectations of -$8.7. Following the earnings report the stock price went up 0.166%.
Which hedge fund is a major shareholder of Helius Medical Technologies?
Currently, no hedge funds are holding shares in HSDT
Helius Medical Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$9.50 (38.28% Upside)
$9.50 (38.28% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.11%
12-Months-Change
Fundamentals
Return on Equity
-344.28%
Trailing 12-Months
Asset Growth
-10.77%
Trailing 12-Months
Company Description
Helius Medical Technologies
Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.
Technical Analysis
Ownership Overview
0.96%
Insiders
3.10% Mutual Funds
<0.01% Other Institutional Investors
99.04% Public Companies and
Individual Investors